MitoTempol for Cognitive Impairment
What You Need to Know Before You Apply
What is the purpose of this trial?
The goal of this clinical trial is to better understand how day-to-day stress affects cardiovascular health and brain function in middle-aged adults. The main question is aims to answer is whether the link between daily stress and vascular dysfunction is a potential mechanism of increased risk for future cognitive decline. Participants will complete two 15-day "testing cycles" separated by \~6 months. During each cycle, participants will complete two daily assessments of stress and brain health using an online survey tool for 14-consecutive days. On the last day of each cycle, vascular function will be assessed during a laboratory visit.
Will I have to stop taking my current medications?
If you are currently using medications that affect heart function or any psychoactive drugs, you will need to stop taking them at least 8 weeks before joining the trial.
Who Is on the Research Team?
Jody Greaney, PhD
Principal Investigator
University of Delaware
Are You a Good Fit for This Trial?
This trial is for middle-aged adults who may be experiencing cognitive impairment. To join, participants must be able to complete online surveys and attend two lab visits about six months apart. Details on specific inclusion or exclusion criteria are not provided.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Ambulatory Assessment
Participants complete daily assessments of stress and cognitive function using a mobile app for 14 consecutive days
Laboratory Assessment
Vascular function is assessed using intradermal microdialysis and laser Doppler flowmetry
Follow-up
Participants are monitored for safety and effectiveness after the assessment cycles
What Are the Treatments Tested in This Trial?
Interventions
- MitoTempol
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Delaware
Lead Sponsor
National Institute of General Medical Sciences (NIGMS)
Collaborator